Best Stocks Under $200 to Buy Today: May 20, 2025
| Number | Ticker | Country | Founded | IPO Year | Price | Revenue | Analyst Decision | Analyst Count |
|---|---|---|---|---|---|---|---|---|
| 1 | Canada | 1953 | N/A | $106.47 | $8,924,178,000.00 | Buy | 8 | |
| 2 | Canada | 1993 | N/A | $13.71 | $5,564,800,000.00 | Buy | 4 | |
| 3 | United States | 2015 | 2017 | $130.60 | $333,448,000.00 | Strong Buy | 8 | |
| 4 | United States | 1975 | 1995 | $48.87 | $1,672,834,000.00 | Buy | 4 | |
| 5 | United States | 1998 | N/A | $52.02 | $1,084,306,000.00 | Buy | 9 | |
| 6 | United States | 2010 | 2021 | $52.56 | $570,399,000.00 | Buy | 16 | |
| 7 | India | 1996 | N/A | $55.99 | $1,314,942,000.00 | Buy | 8 | |
| 8 | KRKroger Company (The) | United States | 1883 | N/A | $68.85 | $147,123,000,000.00 | Buy | 15 |
| 9 | Canada | 2003 | 1999 | $24.51 | $1,402,300,000.00 | Buy | 4 | |
| 10 | Ireland | 1990 | 1998 | $132.49 | $8,192,621,999.00 | Buy | 12 | |
| 11 | United States | 1992 | 2008 | $13.16 | $140,923,000.00 | Strong Buy | 4 | |
| 12 | Switzerland | 1945 | N/A | $89.82 | $9,925,000,000.00 | Buy | 11 | |
| 13 | United States | 1984 | 1986 | $166.66 | $20,703,000,000.00 | Strong Buy | 24 | |
| 14 | United States | 1866 | N/A | $37.53 | $8,943,000,000.00 | Buy | 13 | |
| 15 | ANIPANI Pharmaceuticals Inc. | United States | 2001 | N/A | $59.99 | $674,068,000.00 | Strong Buy | 8 |
| 16 | Israel | 1999 | N/A | $17.41 | $419,170,000.00 | Strong Buy | 7 | |
| 17 | United States | 2016 | 2020 | $16.86 | $0.00 | Strong Buy | 4 | |
| 18 | TARSTarsus Pharmaceuticals Inc. | United States | 2016 | 2020 | $43.70 | $233,674,000.00 | Strong Buy | 6 |
| 19 | United States | N/A | N/A | $11.83 | $194,520,000.00 | Strong Buy | 6 | |
| 20 | United States | 2015 | 2019 | $33.84 | $127,415,000.00 | Strong Buy | 12 | |
| 21 | SRPTSarepta Therapeutics Inc. (DE) | United States | 1980 | 1997 | $36.43 | $2,233,371,000.00 | Buy | 23 |
| 22 | United States | 2007 | 2021 | $15.04 | $685,280,000.00 | Buy | 12 | |
| 23 | PRMBPrimo Brands Corporation Class A Common Stock | United States | 1955 | N/A | $32.32 | $5,630,400,000.00 | Strong Buy | 7 |
| 24 | United States | 2011 | 2018 | $40.67 | $773,996,000.00 | Strong Buy | 21 | |
| 25 | United States | 1997 | 2004 | $31.00 | $19,218,000.00 | Buy | 18 | |
| 26 | United States | 1996 | 2017 | $15.64 | $104,970,000.00 | Buy | 9 | |
| 27 | United States | 2007 | 2019 | $16.75 | $347,083,000.00 | Strong Buy | 6 | |
| 28 | United States | 2017 | N/A | $21.30 | $215,981,000.00 | Buy | 9 | |
| 29 | United States | 2013 | 2021 | $15.78 | $3,001,892,000.00 | Buy | 11 | |
| 30 | XENEXenon Pharmaceuticals Inc. | Canada | 1996 | 2014 | $30.29 | $7,500,000.00 | Strong Buy | 11 |
| 31 | United States | 2013 | 2018 | $30.93 | $347,680,000.00 | Buy | 10 | |
| 32 | Canada | 1994 | 1995 | $22.75 | $2,990,700,000.00 | Buy | 4 | |
| 33 | Canada | 1986 | 2007 | $159.27 | $1,212,000,000.00 | Buy | 8 | |
| 34 | United States | 2008 | N/A | $16.80 | $273,533,000.00 | Strong Buy | 14 | |
| 35 | United States | 2014 | 2020 | $27.78 | $728,303,000.00 | Strong Buy | 13 | |
| 36 | United States | 1999 | 2000 | $21.23 | $109,112,000.00 | Strong Buy | 5 | |
| 37 | United States | 1857 | N/A | $73.28 | $2,428,300,000.00 | Buy | 9 | |
| 38 | TGTXTG Therapeutics Inc. | United States | 1993 | 1995 | $34.36 | $386,386,000.00 | Strong Buy | 5 |
| 39 | GGenpact Limited | Bermuda | 1997 | 2007 | $44.19 | $4,850,828,000.00 | Buy | 8 |
| 40 | United States | 1956 | 2015 | $81.24 | $1,536,699,000.00 | Strong Buy | 5 | |
| 41 | United States | 1965 | N/A | $21.43 | $10,991,521,000.00 | Buy | 4 | |
| 42 | Canada | 2016 | N/A | $19.89 | $293,708,000.00 | Strong Buy | 5 | |
| 43 | United States | 1901 | N/A | $40.36 | $15,207,000,000.00 | Buy | 5 |
Share on Social Networks:
Disclaimer
The FinQuota filters have identified what they believe to be the "Best Under $200 Stocks to Buy on May 20, 2025" to buy now. However, please note that this information should not be considered as financial advice, as investing involves risks. We strongly recommend consulting with a qualified financial advisor before making any decisions regarding buying or selling stocks.